TScan Therapeutics (TCRX) Cash from Operations Growth (1y) (2021 - 2026)
TScan Therapeutics (TCRX) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | TScan Therapeutics | 100.59 Mn | -27.47 Mn | - | 35.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.40% |
| Dec 31, 2025 | -16.74% |
| Sep 30, 2025 | -16.28% |
| Jun 30, 2025 | -26.85% |
| Mar 31, 2025 | -28.42% |
| Dec 31, 2024 | -15.34% |
| Sep 30, 2024 | -448.24% |
| Jun 30, 2024 | -19.09% |
| Mar 31, 2024 | -24.08% |
| Dec 31, 2023 | -48.44% |
| Sep 30, 2023 | 147.15% |
| Jun 30, 2023 | -64.75% |
| Mar 31, 2023 | -17.21% |
| Dec 31, 2022 | -11.34% |
| Sep 30, 2022 | -24.65% |
| Jun 30, 2022 | -24.93% |
| Mar 31, 2022 | -102.11% |
| Dec 31, 2021 | -95.65% |
| Sep 30, 2021 | -135.62% |